Abstract
Drug delivery systems (DDSs) based on nanomaterials have shown a promise for cancer chemotherapy; however, it remains a great challenge to localize on-demand release of anticancer drugs in tumor tissues to improve therapeutic effects and minimize the side effects. In this regard, photoresponsive DDSs that employ light as an external stimulus can offer a precise spatiotemporal control of drug release at desired sites of interest. Most photoresponsive DDSs are only responsive to ultraviolet-visible light that shows phototoxicity and/or shallow tissue penetration depth, and thereby their applications are greatly restricted. To address these issues, near-infrared (NIR) photoresponsive DDSs have been developed. In this review, the development of NIR photoresponsive DDSs in last several years for cancer photo-chemotherapy are summarized. They can achieve on-demand release of drugs into tumors of living animals through photothermal, photodynamic, and photoconversion mechanisms, affording obviously amplified therapeutic effects in synergy with phototherapy. Finally, the existing challenges and further perspectives on the development of NIR photoresponsive DDSs and their clinical translation are discussed.
Similar content being viewed by others
Introduction
Chemotherapy is one of the most common treatment strategies in the clinic for cancer, which however often has the issues of low therapeutic efficacy, intrinsic drug resistance and severe side effects [1,2,3]. Although nanomaterial-based drug delivery systems (DDSs) can mitigate the problems [4,5,6,7], ineluctable accumulation of therapeutic drugs in healthy tissues is still prominent. In contrast, stimuli-responsive DDSs with controllable on-demand drug release profiles have been demonstrated to allow highly specific cancer treatment with reduced toxic concerns to normal tissues [8,9,10]. Within the exciting stimuli-responsive DDSs, typical controlled release of drugs mainly relies on some endogenous reactions in the biological systems, such as, cleavages of reactive oxygen species (ROS)-responsive moieties by oxidative stress [33]. Although there are various light-sensitive moieties that are responsive to ultraviolet (UV)–visible light, their applications in DDSs are restricted by the high phototoxicity of UV light and shallow tissue penetration depths for both UV and visible lights (< 1 mm) [34,35,36]. In contrast, near-infrared (NIR) light (650–950 nm) displays negligible phototoxicity and can penetrate more deeply into biological tissues (1–3.5 mm) [37]. In the presence of suitable optical materials as the transducers, NIR light can be converted into heat for photothermal therapy (PTT), ROS for photodynamic therapy (PDT), and UV/visible photons for photoregulation [38,39,40]. Therefore, it is feasible to integrate thermal-, ROS- and short-wavelength light-sensitive components into DDSs to achieve photoresponsive drug release for precise cancer therapy.
Herein, we summarize the recent development of NIR photoresponsive DDSs with on-demand drug release profiles for cancer photo-chemotherapy. They are first classified into (i) photothermal responsive DDSs, (ii) photodynamic responsive DDSs, and (iii) photoconversion responsive DDSs based on three different photoresponsive mechanisms. The constructions, NIR light triggered drug release profiles of these DDSs, and their applications for cancer therapy are then introduced. At last, a brief conclusion and discussion of the existing challenges and further perspectives are given.
Classification of photoresponsive DDSs
NIR photoresponsive DDSs can be classified into three categories: (i) photothermal responsive DDSs, (ii) photodynamic responsive DDSs, and (iii) photoconversion responsive DDSs according to different mechanisms. For cancer therapy, DDSs are typically administered via intravenous injection, and accumulate into tumor tissues though the enhanced permeability and retention (EPR) effect [41]. The representative NIR photoresponsive DDSs used for synergetic treatments of tumors in living animals are listed in Table 1.
Photothermal responsive DDSs achieve on-demand release of drugs via nanomaterial-mediated PTT under NIR laser irradiation to generate heat to destroy thermal-responsive materials (Fig. 1) [42]. Such a class of DDSs are generally constructed via integrating thermal-responsive components into nanomaterials containing drugs and photothermal agents [43, 44]. Due to the excellent photothermal conversion efficacy, NIR-absorbing dyes, polydopamine, Prussian blue, carbon, copper sulfide (CuS), bismuth sulfide (Bi2S3), and gold (Au) nanoparticles have been widely utilized to fabricate photothermal responsive DDSs.
Photodynamic responsive DDSs rely on photosensitizer-mediated PDT to allow NIR triggered drug release (Fig. 1) [45]. PDT utilizes photosensitizers and light irradiation to generate ROS to induce cancer cell death [46]. Meanwhile, the hypoxic condition of tumors will be aggravated due to the continuous consumption of oxygen molecules in PDT process [47]. In view of this, integrations of ROS- and hypoxia-sensitive moieties into DDSs enable the development of ROS- and hypoxia-responsive DDSs, respectively [31]. The common photosensitizers for PDT include tetraphenylchlorin (TPC), indocyanine green (ICG), Rose bengal (RB), chlorin e6 (Ce6), porphyrin, pheophorbide A (PhA), boron dipyrromethene (BODIPY), conjugated polymer (CP), and semiconducting polymer (SP). Among them, ICG has been approved by the US Food and Drug Administration (FDA) for the clinical diagnosis and phototherapy [31].
Photoconversion responsive DDSs are fabricated through integrating UV/visible light-sensitive components (such as 2-nitrobenzyl, spiropyran, coumarin, 7-nitroindoli, donor–acceptor Stenhouse adduct, and azobenzene) into upconverting nanosystems with loadings or conjugations of drugs [68,69,70]. For example, Kim and Yong et al. constructed a mesoporous silica coated silver–gold hollow nanoplatform to precisely regulate the release of 5-fluorouracil (anticancer drug) for prostate cancer therapy and photothermal therapy [70]. The mesopores were capped with a thermosensitive PCM (lauric acid), which allowed for remote, precise, and spatiotemporal control of drug release via silver–gold nanoshell-mediated photothermal heating under NIR laser irradiation at 808 nm. Such a nanoplatform thus showed a synergistic effect in killing cancer cells. Since MSNs do not have photothermal effect, other photothermal agents are required to construct these MSN-based photothermal responsive DDSs.
Qian’s group developed a photothermal responsive DDS based on rod-based urchin-like Bi2S3 hollow nanoparticles (termed as U-BSHM) to allow precise release of chemotherapeutic agents for synergistic PTT/chemotherapy [71]. A sacrificial template engaged polyol route was used to synthesize U-BSHM as the photothermal agent with a photothermal conversion efficiency of 26.8%. U-BSHM was loaded with DOX and encapsulated with PCM of 1-tetradecanol (the melting point at around 38 °C) as the “gatekeeper” to form the photothermal responsive DDS (termed as PD@BS) (Fig. 4a). The release of DOX was rapidly increased upon NIR laser irradiation at 808 nm compared to that without laser irradiation (Fig. 4b). The cell viability of MDA-MB-231 cancer cells gradually decreased with the prolonged NIR laser irradiation time and elevated concentrations of DDSs, which was due to the synergetic action of PTT and released DOX induced by NIR laser irradiation. The temperature of MDA-MB-231 tumor regions of living mice after intratumoral injection of PD@BS gradually increased to a plateau of around 49 °C under NIR laser irradiation, which was enough to induce the release of DOX and ablate tumors. As a result, the therapeutic effect of PD@BS was obviously improved with NIR laser irradiation (Fig. 4c).
![figure 4](http://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12951-020-00668-5/MediaObjects/12951_2020_668_Fig4_HTML.png)
(Reproduced from Ref. [71] with permission from Elsevier, copyright 2020)
a Schematic illustration of thermosensitive urchin-like Bi2S3 hollow nanoparticles as photothermal responsive DDSs for photothermal-chemotherapy. b Cumulative release of DOX from PD@BS induced by cyclic “turn-on” and “turn-off” of NIR light at different times. c The growth curves of MDA-MB-231 tumors in different groups during a period of 12 days
Several other photothermal agents have also been used to induce the phase changes of PCM to achieve on-demand releases of chemotherapeutic drugs and synergistic effects of PTT/chemotherapy. Cai and co-workers constructed a photothermal responsive DDS based on hollow magnetic Prussian blue nanoparticles for NIR light-triggered PTT/chemotherapy [72]. Such a DDS consisted of a Prussian blue coated hollow iron oxide magnetic nanoparticle as the carrier and photothermal agent, DOX as the chemotherapeutic drug, and a biocompatible PCM of 1-pentadecanol as the “drug-janitor” for controlled-release in response to increased temperature (> 42 °C). In such a system, the release of DOX from DDS was significantly increased upon 808 nm laser irradiation due to Prussian blue-mediated photothermal effect. After treatments, this system exerted synergistic PTT/chemotherapy and afforded an enhanced therapeutic efficacy in inhibiting the growth of human hepatoma HepG2 tumors compared to sole chemotherapy and PTT. Similarly, Guo’s group developed a mesoporous carbon nanoparticle (MCN)-based DDS filled with DOX and 1-tetradecano as the PCM in hollow cavities for NIR light-triggered release of DOX [73]. The cumulative DOX release was significantly increased under 808 nm laser irradiation via MCN-mediated photothermal effect. A much higher intracellular DOX level was observed in MCF-7/ADR cells after treatment with MCN-based DDS plus laser irradiation relative to those without laser irradiation. The apoptosis evaluation showed that the highest percentage of total apoptosis (49.7%) was caused by MCN-based DDS treatment plus NIR laser irradiation, which was 2.48-fold higher relative to that of free DOX treatment alone. This suggested an enhanced therapeutic effect induced by the NIR light-triggered PTT and drug release.
In addition to PTT/chemotherapy, photothermal responsive PCM-based hollow nanostructures have also been developed for synergistic PTT/PDT/chemotherapy. For example, hollow mesoporous ZrO2-coated Nd3+-doped UCNPs were used as the photothermal nanocarriers to load DOX, Ce6, and 1-tetradecanol (PCM), forming a DDS (termed as UCNPs@ZrO2-Ce6/DOX/PCM) [74]. Due to the UCNP-mediated PTT, the release efficiency upon 808 nm NIR laser irradiation reached 44.12%. The inhibitory effect of HeLa cancer cells after treatment of UCNPs@ZrO2-Ce6/DOX/PCM and laser irradiation reached nearly 100%, which was 3.2-, 2.3-, and 1.6-fold higher than that in sole PTT, free DOX and PTT + PDT group, respectively. An excellent in vivo synergistic antitumor efficacy was also verified in murine cervical U14 tumor-bearing mice after treatment with this nanosystem plus NIR laser irradiation. Similarly, Xu’s group constructed another photothermal responsive DDS (termed as HPDC) with a high photothermal conversion efficiency of 44.13% for synergistic PTT/PDT/chemotherapy [75]. Such a HPDC consisted of four key components: hollow mesoporous CuS nanoparticle as both the photothermal agent and nanocarrier, surface coated 1-tetradecanol as a PCM, DOX as a chemotherapy drug and Ce6 as a photodynamic photosensitizer. NIR laser irradiation at 808 nm increased local temperature via CuS-mediated PTT, which obviously increased the release of both DOX and Ce6. Their cumulative release reached 72.78 and 74.4% after six cycles of NIR laser irradiation, respectively, while only approximately 5% DOX or Ce6 in total was released without laser irradiation. Via HPDC-mediated synergistic PTT/PDT/chemotherapy, the growth of 4T1 tumors in living mice was almost completely inhibited, while other treatments failed to effectively suppress tumor growth.
This section summarizes the recent constructions of photothermal responsive liposomes and PCM-based hollow nanostructures for NIR photoactivated drug release through photothermal effect mediated phase transition of thermal-sensitive materials. The liposomes have intrinsic advantages of good biocompatibility and biodegradability, low toxicity and immunogenicity, tunable physicochemical and biophysical properties and unique capability of loading both lipophilic and hydrophilic drugs [76]. However, liposomes often exhibit low stability because the phospholipid can be easily oxidized and hydrolyzed. Moreover, the use of organic solvent or high temperature during the liposome fabrication process may affect the bioactivity of drug molecules [77]. The hollow nanostructure-based DDSs exhibit various advantages including excellent chemical stability, high drug loading capability, and abundant surface chemical groups for further functionalization [78,79,80]. However, they generally have the drawbacks of poor biodegradability and long-term toxic concerns in living bodies [81]. These disadvantages of photothermal responsive DDSs should be considered to facilitate their translation for clinical medicine.
Photodynamic responsive DDSs
In the typical process of PDT, photosensitizers not only convert light energy into ROS, but also deplete oxygen to increase the tumor hypoxia to a certain extent [47]. Hence, it is feasible to construct photodynamic responsive DDSs via integrating ROS- or hypoxia-cleavable moieties into DDSs.
ROS-responsive DDSs
ROS-responsive DDSs have been applied to selectively release various drugs into target tissues, which can be achieved via photo-controlled cleavage of ROS-responsive linkers [12, 82, 83]. For instance, Schnermann et al. reported the utilization of NIR light to cleave antibody–drug conjugates containing a cyanine photocage [84]. Such conjugates consisted of a heptamethine cyanine fluorophore serving as the photocaging component, combretastatin A4 (CA4) acting as the potent inhibitor of microtubule polymerization and a human epidermal growth factor receptor (EGFR)-binding monoclonal antibody. This linker strategy utilized carbamate functional groups as the antibody attachment points, which ensured the release of CA4 drugs from antibodies triggered by ROS generation form fluorophore under NIR laser irradiation at 690 nm. Moreover, the fluorescence signal of this system provided a useful marker to verify the accumulation of conjugates, while the loss of fluorescence signal after excitation by NIR light indicated drug release.
Another representative example of ROS-responsive DDS was demonstrated by Liu’ s group [85]. In this system, DOX was covalently conjugated to an organic conjugated polyelectrolyte (CPE) through a ROS-cleavable dithioketal linker. PEG chains and cRGD were also conjugated to the backbone of CPE to improve its solubility and target specificity to cancer cells, respectively. CPE was utilized as the photosensitizer to generate ROS upon white light irradiation, not only exerting PDT, but also triggering the cleavage of dithioketal linkers for on-demand DOX release, which permitted a synergistic cancer therapy with an enhanced therapeutic effect. The ROS-cleavable dithioketal linker was also utilized by **, light-harvesting unit integration, and incorporation of different optical materials have shown great potential in amplifying the photon conversion efficiencies [37]. Third, the in vivo long-term biocompatibility and biodegradability of NIR photoresponsive DDSs is questionable and the products of photoirradiation may cause some safety concerns. To address this issue, it is necessary to systemically evaluate their biosafety in living subjects. Alternatively, efforts can be made to enhance their biodegradability and/or reduce their dimensions for a rapid clearance via renal and/or hepatic excretions [121,122,123,124]. Fourth, the variety of photoresponsive components is very limited, and their manufactures require long processing time and high cost of production, which greatly hinders the large-scale manufacturing of photoresponsive DDSs for clinical and translational applications. Exploration of facile inexpensive manufacturing methodology and/or development of new photoresponsive components is desirable to achieve their clinical translation. At last, it is often difficult to identify the tumor regions and the optimal therapeutic windows for NIR laser irradiation. Additional imaging agents can be integrated into photoresponsive DDSs to realize imaging-guided cancer photo-chemotherapy.
In addition to anticancer drugs, NIR photoresponsive DDSs can be used for on-demand release of other agents to achieve different therapeutic purposes. For example, Chang’s group reported the use of Prussian blue nanocubes to mediate photothermic activation of a tumor suppressor gene (p53) for PTT-synergistic gene therapy of tumors [125]. Via integrating photoresponsive components with immunotherapeutic molecules into a single nanoplatform, it is probable to achieve photoactivation of cancer immunotherapy using NIR photoresponsive DDSs [45]. Furthermore, the feasibility of NIR photoresponsive DDSs for the treatments of diseases other than cancer such as neurodegenerative, cardiovascular, infectious, and autoimmune diseases can be explored. Overall, with the progression of extensive research that will enable a better understanding of the current state of art, NIR photoresponsive DDSs should be available for clinical applications in the near future.
Availability of data and materials
Not applicable.
Abbreviations
- DDSs:
-
Drug delivery systems
- NIR:
-
Near-infrared
- ROS:
-
Reactive oxygen species
- UV:
-
Ultraviolet
- PTT:
-
Photothermal therapy
- PDT:
-
Photodynamic therapy
- PCM:
-
Phase change material
- CuS:
-
Copper sulfide
- Bi2S3 :
-
Bismuth sulfide
- TPC:
-
Tetraphenylchlorin
- ICG:
-
Indocyanine green
- RB:
-
Rose bengal
- Ce6:
-
Chlorin e6
- PhA:
-
Pheophorbide A
- BODIPY:
-
Boron dipyrromethene
- CP:
-
Conjugated polymer
- SP:
-
Semiconducting polymer
- UCNPs:
-
Upconverting nanoparticles
- DOX:
-
Doxorubicin
- MCN:
-
Mesoporous carbon nanoparticle
- DSPE-PEG:
-
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(poly(ethylene glycol))]
- MSPC:
-
1-Stearoyl-2-hydroxy-sn-glycero-3-phosphatidylcholine
- DPPC:
-
1,2-Dipalmitoyl-sn-glycero-3-phosphatidylcholine
- DiR:
-
1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide
- ABC:
-
Ammonium bicarbonate
- DTX:
-
Docetaxel
- CPP:
-
Cell-penetrating peptide
- cRGD:
-
Cyclic arginine-glycine-aspartic acid
- PAMAM:
-
Poly(amidoamine)
- TPP:
-
Triphenylphosphine
- DSPC:
-
1,2-Distearoyl-sn-glycero-3-phosphocholine
- LON:
-
Lonidamine
- PTX:
-
Paclitaxel
- TPZ:
-
Tirapazamine
- MSNs:
-
Mesoporous silica nanoparticles
- CA4:
-
Combretastatin A4
- EGFR:
-
Epidermal growth factor receptor
- RBC:
-
Red blood cell
- TPC:
-
Tetraphenylchlorin
- BATA:
-
Bis-(alkylthio)alkene
- BSA:
-
Bovine serum albumin
- PMAA:
-
Poly(methacrylic acid)
- PGA:
-
Poly-ʟ-glutamic acid
- β-CD:
-
β-Cyclodextrin
- HPLC:
-
High-performance liquid chromatography
- SPNs:
-
Semiconducting polymer nanoparticles
- Pt(IV):
-
Platinum (IV)
- PAA:
-
Poly(acrylic acid)
- TAT:
-
Trans-activator of transcription
- HA:
-
Hyaluronic acid
- ANSI:
-
American National Standard Institute
References
Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 2013;65:1866–79.
Browning RJ, Reardon PJT, Parhizkar M, Pedley RB, Edirisinghe M, Knowles JC, Stride E. Drug delivery strategies for platinum-based chemotherapy. ACS Nano. 2017;11:8560–78.
Kim J, Yung BC, Kim WJ, Chen X. Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy. J Control Release. 2017;263:223–30.
Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev. 2016;98:19–34.
Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12:991–1003.
Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C. 2016;60:569–78.
Yang K, Feng L, Liu Z. Stimuli responsive drug delivery systems based on nano-graphene for cancer therapy. Adv Drug Deliv Rev. 2016;105:228–41.
Zhu Y, Shi J, Shen W, Dong X, Feng J, Ruan M, Li Y. Stimuli-responsive controlled drug release from a hollow mesoporous silica sphere/polyelectrolyte multilayer core-shell structure. Angew Chem Int Ed. 2005;12:5083–7.
Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release. 2008;126:187–204.
Yin Q, Shen J, Zhang Z, Yu H, Li Y. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv Drug Deliv Rev. 2013;65:1699–715.
Yin W, Ke W, Chen W, ** L, Zhou Q, Mukerabigwi JF, Ge Z. Integrated block copolymer prodrug nanoparticles for combination of tumor oxidative stress amplification and ROS-responsive drug release. Biomaterials. 2019;195:63–74.
Saravanakumar G, Kim J, Kim WJ. Reactive-oxygen-species-responsive drug delivery systems: promises and challenges. Adv Sci. 2017;4:1600124.
Lee SH, Gupta MK, Bang JB, Bae H, Sung HJ. Current progress in reactive oxygen species (ROS)-responsive materials for biomedical applications. Adv Healthc Mater. 2013;2:908–15.
Zhou T, Zhou X, **ng D. Controlled release of doxorubicin from graphene oxide based charge-reversal nanocarrier. Biomaterials. 2014;35:4185–94.
Zhang Y, Teh C, Li M, Ang CY, Tan SY, Qu Q, Korzh V, Zhao Y. Acid-responsive polymeric doxorubicin prodrug nanoparticles encapsulating a near-infrared dye for combined photothermal-chemotherapy. Chem Mater. 2016;28:7039–50.
Xu C, Yan Y, Tan J, Yang D, Jia X, Wang L, Xu Y, Cao S, Sun S. Biodegradable nanoparticles of polyacrylic acid-stabilized amorphous CaCO3 for tunable pH-responsive drug delivery and enhanced tumor inhibition. Adv Funct Mater. 2019;29:1808146.
Liu J, Zhang B, Luo Z, Ding X, Li J, Dai L, Zhou J, Zhao X, Ye J, Cai K. Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo. Nanoscale. 2015;7:3614–26.
Lee SJ, Jeong Y-I, Park H-K, Kang DH, Oh J-S, Lee S-G, Lee HC. Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery. Int J Nanomed. 2015;10:5489.
Hu Q, Katti PS, Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. Nanoscale. 2014;6:12273–86.
Chen J, Ding J, Wang Y, Cheng J, Ji S, Zhuang X, Chen X. Sequentially responsive shell-stacked nanoparticles for deep penetration into solid tumors. Adv Mater. 2017;29:1701170.
Chi Y, Yin X, Sun K, Feng S, Liu J, Chen D, Guo C, Wu Z. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J Control Release. 2017;261:113–25.
Sun B, Luo C, Yu H, Zhang X, Chen Q, Yang W, Wang M, Kan Q, Zhang H, Wang Y. Disulfide bond-driven oxidation-and reduction-responsive prodrug nanoassemblies for cancer therapy. Nano Lett. 2018;18:3643–50.
Li Y, Lu A, Long M, Cui L, Chen Z, Zhu L. Nitroimidazole derivative incorporated liposomes for hypoxia-triggered drug delivery and enhanced therapeutic efficacy in patient-derived tumor xenografts. Acta Biomater. 2019;83:334–48.
Liu H, **e Y, Zhang Y, Cai Y, Li B, Mao H, Liu Y, Lu J, Zhang L, Yu R. Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. Biomaterials. 2017;121:130–43.
Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11:843–52.
Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, Delaria K, Lui V, Poulsen K, Loo C. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug Chem. 2015;26:650–9.
Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother. 2013;62:217–23.
Karimi M, Sahandi Zangabad P, Baghaee-Ravari S, Ghazadeh M, Mirshekari H, Hamblin MR. Smart nanostructures for cargo delivery: uncaging and activating by light. J Am Chem Soc. 2017;139:4584–610.
Hyun DC, Lu P, Choi SI, Jeong U, **a Y. Microscale polymer bottles corked with a phase-change material for temperature-controlled release. Angew Chem Int Ed. 2013;52:10468–71.
Moon GD, Choi S-W, Cai X, Li W, Cho EC, Jeong U, Wang LV, **a Y. A new theranostic system based on gold nanocages and phase-change materials with unique features for photoacoustic imaging and controlled release. J Am Chem Soc. 2011;133:4762–5.
Li J, Pu K. Semiconducting polymer nanomaterials as near-infrared photoactivatable protherapeutics for cancer. Acc Chem Res. 2020;53:752–62.
**ong Q, Lim Y, Li D, Pu K, Liang L, Duan H. Photoactive nanocarriers for controlled delivery. Adv Funct Mater. 2020;30:1903896.
Shaker MA, Younes HM. Photo-irradiation paradigm: map** a remarkable facile technique used for advanced drug, gene and cell delivery. J Control Release. 2015;217:10–26.
Fomina N, McFearin C, Sermsakdi M, Edigin O, Almutairi A. UV and near-IR triggered release from polymeric nanoparticles. J Am Chem Soc. 2010;132:9540–2.
Gnanasammandhan MK, Idris NM, Bansal A, Huang K, Zhang Y. Near-IR photoactivation using mesoporous silica-coated NaYF4:Yb, Er/Tm upconversion nanoparticles. Nat Protoc. 2016;11:688.
Li J, Pu K. Development of organic semiconducting materials for deep-tissue optical imaging, phototherapy and photoactivation. Chem Soc Rev. 2019;48:38–71.
Li J, Duan H, Pu K. Nanotransducers for near-infrared photoregulation in biomedicine. Adv Mater. 2019;31:1901607.
Hessel CM, Pattani VP, Rasch M, Panthani MG, Koo B, Tunnell JW, Korgel BA. Copper selenide nanocrystals for photothermal therapy. Nano Lett. 2011;11:2560–6.
Vankayala R, Kuo CL, Nuthalapati K, Chiang CS, Hwang KC. Nucleus-targeting gold nanoclusters for simultaneous in vivo fluorescence imaging, gene delivery, and NIR-light activated photodynamic therapy. Adv Funct Mater. 2015;25:5934–45.
Jayakumar MKG, Idris NM, Zhang Y. Remote activation of biomolecules in deep tissues using near-infrared-to-UV upconversion nanotransducers. Proc Natl Acad Sci USA. 2012;109:8483–8.
Yang G, Liu J, Wu Y, Feng L, Liu Z. Near-infrared-light responsive nanoscale drug delivery systems for cancer treatment. Coord Chem Rev. 2016;320–321:100–17.
Luo L, Zhu C, Yin H, Jiang M, Zhang J, Qin B, Luo Z, Yuan X, Yang J, Li W. Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors. ACS Nano. 2018;12:7647–62.
Li H, Li J, Ke W, Ge Z. A near-infrared photothermal effect-responsive drug delivery system based on indocyanine green and doxorubicin-loaded polymeric micelles mediated by reversible diels-alder reaction. Macromol Rapid Commun. 2015;36:1841–9.
Ryu T-K, Baek S-W, Kang R-H, Jeong K-Y, Jun D-R, Choi S-W. Photodynamic and photothermal tumor therapy using phase-change material nanoparticles containing chlorin e6 and nanodiamonds. J Control Release. 2018;270:237–45.
Li J, Cui D, Huang J, He S, Yang Z, Zhang Y, Luo Y, Pu K. Organic semiconducting pro-nanostimulants for near-infrared photoactivatable cancer immunotherapy. Angew Chem Int Ed. 2019;58:12680–7.
Cheng L, Wang C, Feng L, Yang K, Liu Z. Functional nanomaterials for phototherapies of cancer. Chem Rev. 2014;114:10869–939.
Henderson BW, Fingar VH. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res. 1987;47:3110–4.
He S, Krippes K, Ritz S, Chen Z, Best A, Butt H-J, Mailänder V, Wu S. Ultralow-intensity near-infrared light induces drug delivery by upconverting nanoparticles. Chem Commun. 2015;51:431–4.
Zhen X, **e C, Jiang Y, Ai X, **ng B, Pu K. Semiconducting photothermal nanoagonist for remote-controlled specific cancer therapy. Nano Lett. 2018;18:1498–505.
Shen S, Zhu C, Huo D, Yang M, Xue J, **a Y. A hybrid nanomaterial for the controlled generation of free radicals and oxidative destruction of hypoxic cancer cells. Angew Chem Int Ed. 2017;56:8801–4.
Mathiyazhakan M, Wiraja C, Xu C. A concise review of gold nanoparticles-based photo-responsive liposomes for controlled drug delivery. Nano-Micro Lett. 2018;10:10.
Lokerse WJ, Bolkestein M, ten Hagen TL, de Jong M, Eggermont AM, Grüll H, Koning GA. Investigation of particle accumulation, chemosensitivity and thermosensitivity for effective solid tumor therapy using thermosensitive liposomes and hyperthermia. Theranostics. 2016;6:1717.
Mazzotta E, Tavano L, Muzzalupo R. Thermo-sensitive vesicles in controlled drug delivery for chemotherapy. Pharmaceutics. 2018;10:150.
Dong Z, Feng L, Chao Y, Hao Y, Chen M, Gong F, Han X, Zhang R, Cheng L, Liu Z. Amplification of tumor oxidative stresses with liposomal fenton catalyst and glutathione inhibitor for enhanced cancer chemotherapy and radiotherapy. Nano Lett. 2018;19:805–15.
Zhu C, Huo D, Chen Q, Xue J, Shen S, **a Y. A eutectic mixture of natural fatty acids can serve as the gating material for near-infrared-triggered drug release. Adv Mater. 2017;29:1703702.
Zangabad PS, Mirkiani S, Shahsavari S, Masoudi B, Masroor M, Hamed H, Jafari Z, Taghipour YD, Hashemi H, Karimi M. Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications. Nanotechnol Rev. 2018;7:95–122.
Yuan Z, Qu S, He Y, Xu Y, Liang L, Zhou X, Gui L, Gu Y, Chen H. Thermosensitive drug-loading system based on copper sulfide nanoparticles for combined photothermal therapy and chemotherapy in vivo. Biomater Sci. 2018;6:3219–30.
Li X, Wang X, Sha L, Wang D, Shi W, Zhao Q, Wang S. Thermosensitive lipid bilayer-coated mesoporous carbon nanoparticles for synergistic thermochemotherapy of tumor. ACS Appl Mater Interfaces. 2018;10:19386–97.
**ong X, Xu Z, Huang H, Wang Y, Zhao J, Guo X, Zhou S. A NIR light triggered disintegratable nanoplatform for enhanced penetration and chemotherapy in deep tumor tissues. Biomaterials. 2020;245:119840.
Dai Y, Su J, Wu K, Ma W, Wang B, Li M, Sun P, Shen Q, Wang Q, Fan Q. Multifunctional thermosensitive liposomes based on natural phase-change material: near-infrared light-triggered drug release and multimodal imaging-guided cancer combination therapy. ACS Appl Mater Interfaces. 2019;11:10540–53.
Yue C, Yang Y, Song J, Alfranca G, Zhang C, Zhang Q, Yin T, Pan F, Jesús M, Cui D. Mitochondria-targeting near-infrared light-triggered thermosensitive liposomes for localized photothermal and photodynamic ablation of tumors combined with chemotherapy. Nanoscale. 2017;9:11103–18.
Wang Q, Dai Y, Xu J, Cai J, Niu X, Zhang L, Chen R, Shen Q, Huang W, Fan Q. All-in-one phototheranostics: single laser triggers NIR-II fluorescence/photoacoustic imaging guided photothermal/photodynamic/chemo combination therapy. Adv Funct Mater. 2019;29:1901480.
Chen D, Tang Y, Zhu J, Zhang J, Song X, Wang W, Shao J, Huang W, Chen P, Dong X. Photothermal-pH-hypoxia responsive multifunctional nanoplatform for cancer photo-chemo therapy with negligible skin phototoxicity. Biomaterials. 2019;221:119422.
Ding Y, Su S, Zhang R, Shao L, Zhang Y, Wang B, Li Y, Chen L, Yu Q, Wu Y. Precision combination therapy for triple negative breast cancer via biomimetic polydopamine polymer core-shell nanostructures. Biomaterials. 2017;113:243–52.
Sun S, Sun S, Sun Y, Wang P, Zhang J, Du W, Wang S, Liang X. Bubble-manipulated local drug release from a smart thermosensitive cerasome for dual-mode imaging guided tumor chemo-photothermal therapy. Theranostics. 2019;9:8138.
Zhao F, Zhou J, Su X, Wang Y, Yan X, Jia S, Du B. A smart responsive dual aptamers-targeted bubble-generating nanosystem for cancer triplex therapy and ultrasound imaging. Small. 2017;13:1603990.
Wu S, Liu X, Ren J, Qu X. Glutathione depletion in a benign manner by MoS2-based nanoflowers for enhanced hypoxia-irrelevant free-radical-based cancer therapy. Small. 2019;15:1904870.
Hernandez Montoto A, Montes R, Samadi A, Gorbe M, Terrés JM, Cao-Milan R, Aznar E, Ibanez J, Masot R, Marcos MD. Gold nanostars coated with mesoporous silica are effective and nontoxic photothermal agents capable of gate kee** and laser-induced drug release. ACS Appl Mater Interfaces. 2018;10:27644–56.
Yang J, Shen D, Zhou L, Li W, Li X, Yao C, Wang R, El-Toni AM, Zhang F, Zhao D. Spatially confined fabrication of core-shell gold nanocages@mesoporous silica for near-infrared controlled photothermal drug release. Chem Mater. 2013;25:3030–7.
Poudel BK, Soe ZC, Ruttala HB, Gupta B, Ramasamy T, Thapa RK, Gautam M, Ou W, Nguyen HT, Jeong J-H. In situ fabrication of mesoporous silica-coated silver–gold hollow nanoshell for remotely controllable chemo-photothermal therapy via phase-change molecule as gatekeepers. Int J Pharm. 2018;548:92–103.
Zhang C, Li D, Pei P, Wang W, Chen B, Chu Z, Zha Z, Yang X, Wang J, Qian H. Rod-based urchin-like hollow microspheres of Bi2S3: facile synthesis, photo-controlled drug release for photoacoustic imaging and chemo-photothermal therapy of tumor ablation. Biomaterials. 2020;237:119835.
Li J, Zhang F, Hu Z, Song W, Li G, Liang G, Zhou J, Li K, Cao Y, Luo Z. Drug “pent-up” in hollow magnetic Prussian blue nanoparticles for NIR-induced chemo-photothermal tumor therapy with trimodal imaging. Adv Healthc Mater. 2017;6:1700005.
Hussain A, Guo S. NIR-triggered release of DOX from sophorolipid-coated mesoporous carbon nanoparticles with the phase-change material 1-tetradecanol to treat MCF-7/ADR cells. J Mater Chem B. 2019;7:974–85.
Feng L, Gai S, He F, Dai Y, Zhong C, Yang P, Lin J. Multifunctional mesoporous ZrO2 encapsulated upconversion nanoparticles for mild NIR light activated synergistic cancer therapy. Biomaterials. 2017;147:39–52.
Li Q, Sun L, Hou M, Chen Q, Yang R, Zhang L, Xu Z, Kang Y, Xue P. Phase-change material packaged within hollow copper sulfide nanoparticles carrying doxorubicin and chlorin e6 for fluorescence-guided trimodal therapy of cancer. ACS Appl Mater Interfaces. 2018;11:417–29.
Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
Van Tran V, Moon J-Y, Lee Y-C. Liposomes for delivery of antioxidants in cosmeceuticals: challenges and development strategies. J Control Release. 2019;300:114–40.
Du X, Zhao C, Zhou M, Ma T, Huang H, Jaroniec M, Zhang X, Qiao SZ. Hollow carbon nanospheres with tunable hierarchical pores for drug, gene, and photothermal synergistic treatment. Small. 2017;13:1602592.
Li Y, Li N, Pan W, Yu Z, Yang L, Tang B. Hollow mesoporous silica nanoparticles with tunable structures for controlled drug delivery. ACS Appl Mater Interfaces. 2017;9:2123–9.
Song G, Chao Y, Chen Y, Liang C, Yi X, Yang G, Yang K, Cheng L, Zhang Q, Liu Z. All-in-one theranostic nanoplatform based on hollow TaOx for chelator-free labeling imaging, drug delivery, and synergistically enhanced radiotherapy. Adv Funct Mater. 2016;26:8243–54.
Li Y, Shi J. Hollow-structured mesoporous materials: chemical synthesis, functionalization and applications. Adv Mater. 2014;26:3176–205.
Saravanakumar G, Lee J, Kim J, Kim WJ. Visible light-induced singlet oxygen-mediated intracellular disassembly of polymeric micelles co-loaded with a photosensitizer and an anticancer drug for enhanced photodynamic therapy. Chem Commun. 2015;51:9995–8.
Li J, Cui D, Jiang Y, Huang J, Cheng P, Pu K. Near-infrared photoactivatable semiconducting polymer nanoblockaders for metastasis-inhibited combination cancer therapy. Adv Mater. 2019;31:1905091.
Nani RR, Gorka AP, Nagaya T, Kobayashi H, Schnermann MJ. Near-IR light-mediated cleavage of antibody-drug conjugates using cyanine photocages. Angew Chem Int Ed. 2015;54:13635–8.
Yuan Y, Liu J, Liu B. Conjugated-polyelectrolyte-based polyprodrug: targeted and image-guided photodynamic and chemotherapy with on-demand drug release upon irradiation with a single light source. Angew Chem Int Ed. 2014;53:7163–8.
Pei Q, Hu X, Zheng X, Liu S, Li Y, **g X, **e Z. Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy. ACS Nano. 2018;12:1630–41.
Li J, Zhen X, Lyu Y, Jiang Y, Huang J, Pu K. Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics. ACS Nano. 2018;12:8520–30.
Zhen X, Cheng P, Pu K. Recent advances in cell membrane-camouflaged nanoparticles for cancer phototherapy. Small. 2019;15:1804105.
Chen Z, Zhao P, Luo Z, Zheng M, Tian H, Gong P, Gao G, Pan H, Liu L, Ma A, Cai L. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano. 2016;10:10049–57.
Sun H, Su J, Meng Q, Yin Q, Chen L, Gu W, Zhang P, Zhang Z, Yu H, Wang S, Li Y. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv Mater. 2016;28:9581–8.
Lee J, Park J, Singha K, Kim WJ. Mesoporous silica nanoparticle facilitated drug release through cascade photosensitizer activation and cleavage of singlet oxygen sensitive linker. Chem Commun. 2013;49:1545–7.
Yang G, Sun X, Liu J, Feng L, Liu Z. Light-responsive, singlet-oxygen-triggered on-demand drug release from photosensitizer-doped mesoporous silica nanorods for cancer combination therapy. Adv Funct Mater. 2016;26:4722–32.
Ma N, Li Y, Xu H, Wang Z, Zhang X. Dual redox responsive assemblies formed from diselenide block copolymers. J Am Chem Soc. 2009;132:442–3.
Han P, Li S, Cao W, Li Y, Sun Z, Wang Z, Xu H. Red light responsive diselenide-containing block copolymer micelles. J Mater Chem B. 2013;1:740–3.
Tian Y, Zheng J, Tang X, Ren Q, Wang Y, Yang W. Near-infrared light-responsive nanogels with diselenide-cross-linkers for on-demand degradation and triggered drug release. Part Part Syst Charact. 2015;32:547–51.
Uthaman S, Pillarisetti S, Mathew AP, Kim Y, Bae WK, Huh KM, Park I-K. Long circulating photoactivable nanomicelles with tumor localized activation and ROS triggered self-accelerating drug release for enhanced locoregional chemo-photodynamic therapy. Biomaterials. 2020;232:119702.
Chen H, Zeng X, Tham HP, Phua SZF, Cheng W, Zeng W, Shi H, Mei L, Zhao Y. NIR-light-activated combination therapy with a precise ratio of photosensitizer and prodrug using a host-guest strategy. Angew Chem Int Ed. 2019;58:7641–6.
Qian C, Yu J, Chen Y, Hu Q, **ao X, Sun W, Wang C, Feng P, Shen QD, Gu Z. Light-activated hypoxia-responsive nanocarriers for enhanced anticancer therapy. Adv Mater. 2016;28:3313–20.
Zhang K, Zhang Y, Meng X, Lu H, Chang H, Dong H, Zhang X. Light-triggered theranostic liposomes for tumor diagnosis and combined photodynamic and hypoxia-activated prodrug therapy. Biomaterials. 2018;185:301–9.
Cui D, Huang J, Zhen X, Li J, Jiang Y, Pu K. A semiconducting polymer nano-prodrug for hypoxia-activated photodynamic cancer therapy. Angew Chem Int Ed. 2019;58:5920–4.
Wang Z, Sun M, Liu T, Tan X, Zhang H, Zhang X, He Z, Sun J. A surfactant-like chemotherapeutic agent as a nanocarrier for delivering photosensitizers against cancer: a facile drug-delivering-drug strategy. Int J Pharm. 2019;562:313–20.
Senthilkumar T, Zhou L, Gu Q, Liu L, Lv F, Wang S. Conjugated polymer nanoparticles with appended photo-responsive units for controlled drug delivery, release, and imaging. Angew Chem Int Ed. 2018;57:13114–9.
Kienzler MA, Reiner A, Trautman E, Yoo S, Trauner D, Isacoff EY. A red-shifted, fast-relaxing azobenzene photoswitch for visible light control of an ionotropic glutamate receptor. J Am Chem Soc. 2013;135:17683–6.
Gu Z, Yan L, Tian G, Li S, Chai Z, Zhao Y. Recent advances in design and fabrication of upconversion nanoparticles and their safe theranostic applications. Adv Mater. 2013;25:3758–79.
**ang J, Ge F, Yu B, Yan Q, Shi F, Zhao Y. Nanocomplexes of photolabile polyelectrolyte and upconversion nanoparticles for near-infrared light-triggered payload release. ACS Appl Mater Interfaces. 2018;10:20790–800.
Boyer J-C, Carling C-J, Gates BD, Branda NR. Two-way photoswitching using one type of near-infrared light, upconverting nanoparticles, and changing only the light intensity. J Am Chem Soc. 2010;132:15766–72.
Zhao L, Peng J, Huang Q, Li C, Chen M, Sun Y, Lin Q, Zhu L, Li F. Near-infrared photoregulated drug release in living tumor tissue via yolk–shell upconversion nanocages. Adv Funct Mater. 2014;24:363–71.
Huang L, Zhao Y, Zhang H, Huang K, Yang J, Han G. Expanding anti-stokes shifting in triplet-triplet annihilation upconversion for in vivo anticancer prodrug activation. Angew Chem Int Ed. 2017;56:14400–4.
He S, Li C, Zhang Q, Ding J, Liang X-J, Chen X, **ao H, Chen X, Zhou D, Huang Y. Tailoring platinum(IV) amphiphiles for self-targeting all-in-one assemblies as precise multimodal theranostic nanomedicine. ACS Nano. 2018;12:7272–81.
Dai Y, **ao H, Liu J, Yuan Q, Ma P, Yang D, Li C, Cheng Z, Hou Z, Yang P, Lin J. In vivo multimodality imaging and cancer therapy by near-infrared light-triggered trans-platinum pro-drug-conjugated upconverison nanoparticles. J Am Chem Soc. 2013;135:18920–9.
Min Y, Li J, Liu F, Yeow EK, **ng B. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles. Angew Chem Int Ed. 2014;53:1012–6.
Xu J, Kuang Y, Lv R, Yang P, Li C, Bi H, Liu B, Yang D, Dai Y, Gai S. Charge convertibility and near infrared photon co-enhanced cisplatin chemotherapy based on upconversion nanoplatform. Biomaterials. 2017;130:42–55.
Liu J, Bu W, Pan L, Shi J. NIR-triggered anticancer drug delivery by upconverting nanoparticles with integrated azobenzene-modified mesoporous silica. Angew Chem Int Ed. 2013;52:4375–9.
Zhang Y, Zhang Y, Song G, He Y, Zhang X, Liu Y, Ju H. A DNA-azobenzene nanopump fueled by upconversion luminescence for controllable intracellular drug release. Angew Chem Int Ed. 2019;58:18207–11.
Liu C, Zhang Y, Liu M, Chen Z, Lin Y, Li W, Cao F, Liu Z, Ren J, Qu X. A NIR-controlled cage mimicking system for hydrophobic drug mediated cancer therapy. Biomaterials. 2017;139:151–62.
Chen G, Jaskula-Sztul R, Esquibel CR, Lou I, Zheng Q, Dammalapati A, Harrison A, Eliceiri KW, Tang W, Chen H. Neuroendocrine tumor-targeted upconversion nanoparticle-based micelles for simultaneous NIR-controlled combination chemotherapy and photodynamic therapy, and fluorescence imaging. Adv Funct Mater. 2017;27:1604671.
Bagheri A, Arandiyan H, Boyer C, Lim M. Lanthanide-doped upconversion nanoparticles: emerging intelligent light-activated drug delivery systems. Adv Sci. 2016;3:1500437.
Jiang Y, Li J, Zhen X, **e C, Pu K. Dual-peak absorbing semiconducting copolymer nanoparticles for first and second near-infrared window photothermal therapy: a comparative study. Adv Mater. 2018;30:1705980.
Maruoka Y, Nagaya T, Sato K, Ogata F, Okuyama S, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy with combined exposure of external and interstitial light sources. Mol Pharm. 2018;15:3634–41.
Younis MR, Wang C, An R, Wang S, Younis MA, Li Z-Q, Wang Y, Ihsan A, Ye D, **a X-H. Low power single laser activated synergistic cancer phototherapy using photosensitizer functionalized dual plasmonic photothermal nanoagents. ACS Nano. 2019;13:2544–57.
Yu M, Zhou J, Du B, Ning X, Authement C, Gandee L, Kapur P, Hsieh JT, Zheng J. Noninvasive staging of kidney dysfunction enabled by renal-clearable luminescent gold nanoparticles. Angew Chem Int Ed. 2016;55:2787–91.
Repenko T, Rix A, Ludwanowski S, Go D, Kiessling F, Lederle W, Kuehne AJ. Bio-degradable highly fluorescent conjugated polymer nanoparticles for bio-medical imaging applications. Nat Commun. 2017;8:470.
Lei T, Guan M, Liu J, Lin H-C, Pfattner R, Shaw L, McGuire AF, Huang T-C, Shao L, Cheng K-T. Biocompatible and totally disintegrable semiconducting polymer for ultrathin and ultralightweight transient electronics. Proc Natl Acad Sci USA. 2017;114:5107–12.
Huang P, Chen Y, Lin H, Yu L, Zhang L, Wang L, Zhu Y, Shi J. Molecularly organic/inorganic hybrid hollow mesoporous organosilica nanocapsules with tumor-specific biodegradability and enhanced chemotherapeutic functionality. Biomaterials. 2017;125:23–37.
Liu Y, Shu G, Li X, Chen H, Zhang B, Pan H, Li T, Gong X, Wang H, Wu X. Human HSP70 promoter-based Prussian blue nanotheranostics for thermo-controlled gene therapy and synergistic photothermal ablation. Adv Funct Mater. 2018;28:1802026.
Acknowledgements
Not applicable.
Funding
This study was supported by the Key Project of Natural Science Foundation of Anhui Provincial Department of Education, China (KJ2019A0402), and the Provincial Quality Engineering Key Project of Chinese Institutions of Higher Learning (2019mooc590).
Author information
Authors and Affiliations
Contributions
XW, ZX, XZ and HS write the original draft manuscript; JL and ZX review and edit the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that there is no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Wang, X., Xuan, Z., Zhu, X. et al. Near-infrared photoresponsive drug delivery nanosystems for cancer photo-chemotherapy. J Nanobiotechnol 18, 108 (2020). https://doi.org/10.1186/s12951-020-00668-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12951-020-00668-5